ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

GLUE Monte Rosa Therapeutics Inc

5,83
0,23 (4,11%)
Dernière mise à jour : 20:20:05
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Monte Rosa Therapeutics Inc GLUE NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,23 4,11% 5,83 20:20:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,82 5,645 5,85 5,60
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202422:01GLOBEMonte Rosa Therapeutics Announces the Departure of Owen..
14/3/202412:00GLOBEMonte Rosa Therapeutics Announces Fourth Quarter and Full..
11/3/202412:00GLOBEMonte Rosa Therapeutics Announces Initiation of IND Enabling..
31/1/202413:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
08/1/202413:47EDGAR2Form 8-K - Current report
08/1/202413:15GLOBEMonte Rosa Therapeutics Provides Corporate Update and Key..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202413:00GLOBEMonte Rosa Therapeutics to Present at the 42nd Annual J.P...
21/11/202313:00GLOBEMonte Rosa Therapeutics to Present at Piper Sandler..
09/11/202313:27EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEMonte Rosa Therapeutics Announces Third Quarter 2023..
07/11/202316:00GLOBEMonte Rosa Therapeutics Presents Preclinical Data at ACR..
27/10/202313:00GLOBEMonte Rosa Therapeutics to Participate in Upcoming Investor..
26/10/202323:01EDGAR2Form 8-K - Current report
26/10/202322:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/10/202322:30GLOBEMonte Rosa Therapeutics Announces $25 Million Registered..
17/10/202313:55EDGAR2Form 8-K - Current report
17/10/202313:00GLOBEMonte Rosa Therapeutics Announces Interim PK/PD and Clinical..
18/8/202322:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/8/202323:16EDGAR2Form 144 - Report of proposed sale of securities
10/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:19EDGAR2Form 8-K - Current report
10/8/202313:15GLOBEMonte Rosa Therapeutics Announces Second Quarter 2023..
26/7/202313:53EDGAR2Form 8-K - Current report
26/7/202313:30GLOBEMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to..
30/5/202322:30GLOBEMonte Rosa Therapeutics to Present at Upcoming Investor and..
23/5/202313:30GLOBEMonte Rosa Therapeutics Advances Second Development..
11/5/202313:30GLOBEMonte Rosa Therapeutics Announces First Quarter 2023..

Dernières Valeurs Consultées

Delayed Upgrade Clock